{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-004154","form_type":"8-K","ticker":"FBIO","cik":"0001429260","company_name":"Fortress Biotech, Inc.","filed_at":"2025-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.608576+00:00","generated_at":"2026-05-24T01:40:45.650134+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Fortress Biotech posts FY2024 net loss of $55.9M; Checkpoint to be acquired by Sun Pharma","bullets":["Net loss attributable to common stockholders of $55.9M ($2.69/sh) vs $68.7M ($8.47/sh) in FY2023; net revenue $57.7M, down from $84.5M.","FDA approved Emrosi (rosacea) in Nov 2024 and UNLOXCYT (cSCC) in Dec 2024; commercial launch of Emrosi underway.","Checkpoint to be acquired by Sun Pharma for $4.10/sh upfront plus up to $0.70 CVR; Fortress expects ~$28M at closing plus 2.5% royalty.","FDA accepted CUTX-101 NDA for priority review with PDUFA date Sept 30, 2025.","Cash $57.3M as of Dec 31, 2024; paused Series A Preferred dividends in July 2024, deferring ~$0.7M/month."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-004154","json":"https://secwatch.observer/filing/0001558370-25-004154.json","markdown":"https://secwatch.observer/filing/0001558370-25-004154.md","text":"https://secwatch.observer/filing/0001558370-25-004154.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1429260/000155837025004154/0001558370-25-004154-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1429260/000155837025004154/fbio-20250331x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T01:40:45.650134+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}